Year: 2022

EDF announces the success of its senior multi-tranche bond issue, including a green tranche, for a nominal amount of 3 billion euros EDF (BBB CW neg S&P / Baa1 neg Moody’s / BBB+ stable Fitch) has successfully launched on 5 October 2022 a senior bond issue in 3 tranches for a nominal amount of 3 billion euros:€750 million Bond, with a long 4-year maturity and a 3.875% fixed coupon; €1 billion Bond, with a 7-year maturity and a 4.375% fixed coupon; €1.25 billion Green Bond, with a 12-year maturity and a 4.75% fixed coupon.An amount equal to the net proceeds of the Green Bond will be used to finance and/or refinance, in whole or in part, electricity distribution investments as defined in EDF’s Green Financing Framework published in July 2022 (1). Settlement and delivery will take place on 12 October 2022, the date on which...

New York, NY, Oct. 05, 2022 (GLOBE NEWSWIRE) — iQSTEL, Inc. (OTCQX: IQST) (“IQST” or the “Company”), today announced the company has amended a common stock purchase option.  “I believe the amended agreement demonstrates the confidence of an important investor has in iQSTEL’s future,” stated iQSTEL CEO Leandro Iglesias. The original stock purchase option was purchased for $500,000 to purchase 4,800,000 shares of common stock at $2 price, the original stock purchase option also included a cashless exercise feature.  The amended agreement has the investor agreeing to forgo the original cashless exercise feature after the first $1,000,000 cashless exercise in addition to committing to cash exercise schedule favorable to iQSTEL. CEO Leandro Iglesias: “I am pleased with the update to the subject investment agreement,...

NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE DEVELOPMENT OF NFL-101 IN INDIA NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has entered into a partnership to develop NFL-101, the company’s drug candidate for smoking cessation, for the Indian market with Themis Medicare Ltd (NSE – Symbol: THEMISMED; BSE – Script code: 530199) a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available to patients. Themis Medicare Limited (Themis) submitted an IND (Investigational New Drug) application for a Phase II / III clinical trial to the Central Drugs Standard Control Organization (CDSCO), the National Regulatory Authority of India (NRA). India has...

With HCP Boundary, HashiCorp Bolsters its Security Portfolio Built for Cloud Infrastructure Platform Teams LOS ANGELES, Oct. 05, 2022 (GLOBE NEWSWIRE) — HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced the general availability of HashiCorp Cloud Platform (HCP) Boundary, a secure remote access product. With this release, Boundary joins HCP Vault and HCP Consul to provide the industry’s first zero trust security solution to secure applications, networks, and people built for the cloud. As organizations move to the cloud and adopt cloud operating models, they require a different approach to security — commonly referred to as zero trust security — where the default security posture is to trust nothing, authenticate and authorize everything. But the gap between legacy...

FT. MYERS BEACH, Fla., Oct. 05, 2022 (GLOBE NEWSWIRE) — Verizon Frontline deployed its Tactical Humanitarian Operations Response (THOR) vehicle to one of the areas hardest hit by Hurricane Ian. THOR, the first and only private 5G network-capable mobile emergency operations vehicle of its kind, will augment ongoing support of first responders conducting search, rescue, response and recovery missions in and around Ft. Myers Beach, Fla. Verizon Frontline’s THOR joins more than 100 Verizon and Verizon Frontline assets already in place in Florida to help provide public safety agencies with a reliable connection for mission-critical voice, data and video communications. “THOR is one of hundreds of state-of-the-art Verizon Frontline assets and solutions we have deployed across Lee County in particular, and many of the hardest-hit areas...

Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 5.10.2022 at 18.45 EET   Rovio Entertainment Corporation – Repurchase of own shares on 5.10.2022   Rovio Entertainment Corporation  In the Nasdaq Helsinki  Date 5.10.2022Exchange transaction BUYShare trading code ROVIOAmount, shares 31477Average price/share, EUR 5,795267Total cost, EUR 182417,61      Rovio now holds a total of 7 648 888 shares including the shares repurchased on 5.10.2022   On behalf of Rovio Entertainment Corporation     OP Corporate Bank PLC  Further information:Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 RovioIR@rovio.com Distribution:Nasdaq Helsinki LtdKey mediawww.rovio.com About Rovio:Rovio Entertainment Corporation is a global mobile-first games company that creates,...

New key preclinical results and a case study excerpted from our ongoing phase II clinical trial DNV3681 in vitro efficacy is superior to vancomycin and similar to the gold standard, fidaxomicin The prodrug DNV3837 is rapidly converted to DNV3681 in vivo and the active drug mostly concentrates in the GI tract The use of DNV3837 is a potential paradigm shift for CDI treatmentDEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that a poster titled « DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection » is to be presented at the ESCMID/ASM conference taking place in Dublin, from October 4 to 7. The new preclinical data presented show that DNV3681...